Semaglutide 2 mg vial GLP1 (Sema G)

Satus:

Available

Shipping:

1-3 business days DHL, FedEx

Chemical reagent

Semaglutide 2 mg is a synthetic GLP-1 (glucagon-like peptide-1) analogue under study for incretin signaling, regulation of glucose metabolism, and energy balance control mechanisms. The molecule was designed to prolong biological stability through structural modifications that increase binding to albumin.

59.00 €

Choose

Freeze-dried (powdered)
Solution

Clear

-10%

for a second product

-20%

for the fourth product

European Shipping

1-3 business days

Warranty
quality

Reviewed
products

Semaglutide 2 mg vial - characteristics of the peptide

Semaglutide 2 mg is a synthetic GLP-1 (glucagon-like peptide-1) analogue belonging to the class of GLP-1 receptor agonists. This compound has been widely reported in the scientific literature in the context of regulation of glucose metabolism, incretin signaling and mechanisms of energy balance control.

Product offered as research material (Research Use Only).

What is semaglutide 2 mg and what is its mechanism of action?

Semaglutide is a modified analog of human GLP-1 with an extended duration of action, achieved through structural modifications that increase the molecule's stability and binding to albumin.

The mechanism of action includes:

activation GLP-1 receptor,
stimulation of glucose-dependent insulin secretion,
Inhibition of glucagon secretion,
Modulation of satiety signaling in the central nervous system,
effect on gastric emptying.

Unlike tirzepatide, semaglutide acts selectively on the GLP-1 receptor (without activating GIP).

Data from clinical trials

Clinical trials of the STEP program (New England Journal of Medicine, 2021) evaluated the effects of semaglutide on body weight in obese or overweight individuals.

At 68-week follow-up for the therapeutic dose:

The average weight reduction was about 14.9%,
in the placebo group about 2.4%,
Improvements in metabolic parameters were also observed.

Type 2 diabetes studies have shown a significant effect on reducing HbA1c compared to placebo.

Source:
Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM, 2021.

Qualitative information

Offered semaglutide 2 mg is subject to qualitative analysis (e.g., HPLC) to confirm purity and compliance with laboratory specifications.

The product is not a medicinal product or supplement.
Intended for research and analytical applications only.

he improvements in glycemia, lipid profile and blood pressure were observed.

Semaglutide differs from newer drugs such as Tirzepatide (GLP-1/GIP receptor agonist) and retatrutide (GLP-1/GIP/glucagon agonist), which have a broader spectrum of metabolic effects, but semaglutide remains one of the best studied and most effective GLP-1 agonists available clinically.

Sources:

Once-Weekly Semaglutide in Adults with Overweight or Obesity (NEJM)

Once-Weekly Semaglutide in Adults with Overweight or Obesity (PubMed)

Product intended for scientific research and laboratory analysis. All articles and information on this site are for informational and educational purposes only.

Laboratory tests to confirm the quality and authenticity of products

INTENDED FOR RESEARCH PURPOSES!
All properties mentioned above are observed with laboratory tests, not done on humans, and are for informational purposes only. Any information contained in the descriptions has not been approved by GIS, GIF or EFSA. The substance is not a drug, food product or dietary supplement, consequently it is not suitable for human consumption. The product qualifies as a chemical reagent / reference material approved for marketing in the EU. It can only be used for scientific research. For other information on the agent, please refer to the Material Safety Data Sheet, which is available for review. The products are available only to institutions or individuals who are associated with research or laboratory activities.